LOGIN  |  REGISTER
C4 Therapeutics
Amneal Pharmaceuticals

Community Health Systems to Webcast First Quarter 2023 Conference Call

April 12, 2023 | Last Trade: US$3.01 0.10 3.44

FRANKLIN, Tenn. / Apr 12, 2023 / Business Wire / Community Health Systems, Inc. (NYSE:CYH) today announced that it will webcast its first quarter 2023 conference call.

The Company will issue a press release announcing its results on Monday, May 1, 2023, after the regular close of trading. The conference call is scheduled to begin at 10:00 a.m. Central time, 11:00 a.m. Eastern time, on Tuesday, May 2, 2023. A live webcast of the conference call will be available online at www.chs.net. The online replay will follow shortly after the call and continue for approximately 30 days.

During this call, Community Health Systems will review the Company’s financial and operating results for the first quarter ended March 31, 2023.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company's affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 44 distinct markets across 15 states. CHS subsidiaries own or lease 78 affiliated hospitals with approximately 13,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. More information about the Company can be found on its website at www.chs.net.

Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page